NCI-MATCH: 6000-strong precision medicine trial publishes first report

Written by Louis Gautier, Future Science Group


NCI-MATCH is the largest precision medicine trial to date and the first set of recently published data gives significant insight into how genomic testing can benefit targeted therapy choice in a huge number of patients. The trial arose through a partnership between the ECOG-ACRIN Cancer Research Group and the National Cancer Institute (NCI; MD, USA) to investigate Molecular Analysis for Therapy Choice (MATCH). The trial sought to identify targeted treatments for patients with relapsed, refractory cancers, regardless of cancer type, both common and rare. The trial opened in August of 2015 and accrued the first 6000 patients over 2 years....

To view this content, please register now for access

It's completely free